Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles

Steven L. Baldwin; Neelesh R. Soman; Gregory M. Lanza; Samuel A. Wickline

doi:10.1109/ULTSYM.2008.0136

Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles

Steven L. Baldwin
, Neelesh R. Soman
, Gregory M. Lanza
, Samuel A. Wickline

Research output: Contribution to journal › Conference article › peer-review

Abstract

Background and Objective: Augmentation of local drug delivery from targeted nanoparticles (NP) with nondestructive, noncavitational clinical ultrasound (US) offers the potential to enhance therapeutic efficacy in diseases such as cancer while limiting adverse systemic side effects. This lab has demonstrated augmentation of drug delivery from avβ3-targeted perfluorocarbon NP and US in cancer cells in vitro (Crowder et al., 2005). The present study investigates the utility of conventional, clinical US for augmentation of drug delivery in vivo in a transgenic mouse cancer model (K14-HPV16) that develops squamous cell carcinomas.

Original language	English
Article number	4803564
Pages (from-to)	566-569
Number of pages	4
Journal	Proceedings - IEEE Ultrasonics Symposium
DOIs	https://doi.org/10.1109/ULTSYM.2008.0136
State	Published - 2008
Event	2008 IEEE International Ultrasonics Symposium, IUS 2008 - Beijing, China Duration: Nov 2 2008 → Nov 5 2008

Keywords

Cancer
In vivo
Nanoparticles
Therapy
Ultrasound

Access to Document

10.1109/ULTSYM.2008.0136

Cite this

@article{4b961d114277478194601fb48cb322ae,

title = "Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles",

abstract = "Background and Objective: Augmentation of local drug delivery from targeted nanoparticles (NP) with nondestructive, noncavitational clinical ultrasound (US) offers the potential to enhance therapeutic efficacy in diseases such as cancer while limiting adverse systemic side effects. This lab has demonstrated augmentation of drug delivery from avβ3-targeted perfluorocarbon NP and US in cancer cells in vitro (Crowder et al., 2005). The present study investigates the utility of conventional, clinical US for augmentation of drug delivery in vivo in a transgenic mouse cancer model (K14-HPV16) that develops squamous cell carcinomas.",

keywords = "Cancer, In vivo, Nanoparticles, Therapy, Ultrasound",

author = "Baldwin, \{Steven L.\} and Soman, \{Neelesh R.\} and Lanza, \{Gregory M.\} and Wickline, \{Samuel A.\}",

year = "2008",

doi = "10.1109/ULTSYM.2008.0136",

language = "English",

pages = "566--569",

journal = "Proceedings - IEEE Ultrasonics Symposium",

issn = "1051-0117",

note = "2008 IEEE International Ultrasonics Symposium, IUS 2008 ; Conference date: 02-11-2008 Through 05-11-2008",

}

TY - JOUR

T1 - Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles

AU - Baldwin, Steven L.

AU - Soman, Neelesh R.

AU - Lanza, Gregory M.

AU - Wickline, Samuel A.

PY - 2008

Y1 - 2008

N2 - Background and Objective: Augmentation of local drug delivery from targeted nanoparticles (NP) with nondestructive, noncavitational clinical ultrasound (US) offers the potential to enhance therapeutic efficacy in diseases such as cancer while limiting adverse systemic side effects. This lab has demonstrated augmentation of drug delivery from avβ3-targeted perfluorocarbon NP and US in cancer cells in vitro (Crowder et al., 2005). The present study investigates the utility of conventional, clinical US for augmentation of drug delivery in vivo in a transgenic mouse cancer model (K14-HPV16) that develops squamous cell carcinomas.

AB - Background and Objective: Augmentation of local drug delivery from targeted nanoparticles (NP) with nondestructive, noncavitational clinical ultrasound (US) offers the potential to enhance therapeutic efficacy in diseases such as cancer while limiting adverse systemic side effects. This lab has demonstrated augmentation of drug delivery from avβ3-targeted perfluorocarbon NP and US in cancer cells in vitro (Crowder et al., 2005). The present study investigates the utility of conventional, clinical US for augmentation of drug delivery in vivo in a transgenic mouse cancer model (K14-HPV16) that develops squamous cell carcinomas.

KW - Cancer

KW - In vivo

KW - Nanoparticles

KW - Therapy

KW - Ultrasound

UR - https://www.scopus.com/pages/publications/67649383661

U2 - 10.1109/ULTSYM.2008.0136

DO - 10.1109/ULTSYM.2008.0136

M3 - Conference article

AN - SCOPUS:67649383661

SN - 1051-0117

SP - 566

EP - 569

JO - Proceedings - IEEE Ultrasonics Symposium

JF - Proceedings - IEEE Ultrasonics Symposium

M1 - 4803564

T2 - 2008 IEEE International Ultrasonics Symposium, IUS 2008

Y2 - 2 November 2008 through 5 November 2008

ER -

Noncavitational nonporative ultrasound elicits marked in vivo augmentation of tumor drug delivery with perfluorocarbon nanoparticles

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this